About AngioDynamics, Inc.
https://www.angiodynamics.comAngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
CEO
James C. Clemmer
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 84
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:4.6M
Value:$47.1M
DIVISADERO STREET CAPITAL MANAGEMENT, LP
Shares:3.68M
Value:$37.63M
BLACKROCK, INC.
Shares:3.47M
Value:$35.55M
Summary
Showing Top 3 of 194
About AngioDynamics, Inc.
https://www.angiodynamics.comAngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $79.43M ▲ | $44.63M ▼ | $-6.35M ▲ | -7.99% ▲ | $-0.15 ▲ | $-436K ▲ |
| Q1-2026 | $75.71M ▼ | $52.51M ▲ | $-10.9M ▼ | -14.4% ▼ | $-0.26 ▼ | $-4.81M ▼ |
| Q4-2025 | $80.16M ▲ | $48.01M ▼ | $-6.05M ▼ | -7.55% ▼ | $-0.15 ▼ | $2.2M ▲ |
| Q3-2025 | $72M ▼ | $48.83M ▼ | $-4.41M ▲ | -6.12% ▲ | $-0.11 ▲ | $-329K ▼ |
| Q2-2025 | $72.84M | $51M | $-10.74M | -14.74% | $-0.26 | $1.79M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $41.64M ▲ | $269.68M ▲ | $93.35M ▲ | $176.33M ▼ |
| Q1-2026 | $38.76M ▼ | $265.64M ▼ | $86.79M ▼ | $178.85M ▼ |
| Q4-2025 | $55.89M ▲ | $280.14M ▼ | $97.17M ▼ | $182.97M ▼ |
| Q3-2025 | $44.76M ▼ | $285.42M ▼ | $99.55M ▼ | $185.87M ▼ |
| Q2-2025 | $54.09M | $291.55M | $104.78M | $186.77M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-6.35M ▲ | $4.66M ▲ | $-1.62M ▼ | $-92K ▼ | $2.88M ▲ | $4.24M ▲ |
| Q1-2026 | $-10.9M ▼ | $-15.91M ▼ | $-1.55M ▲ | $143K ▲ | $-17.13M ▼ | $-16.64M ▼ |
| Q4-2025 | $-6.05M ▼ | $18.81M ▲ | $-2.62M ▲ | $-5.77M ▼ | $11.13M ▲ | $18.03M ▲ |
| Q3-2025 | $-4.41M ▲ | $-13.16M ▼ | $-3.19M ▼ | $7.15M ▲ | $-9.33M ▼ | $-14.96M ▼ |
| Q2-2025 | $-10.74M | $2.47M | $-1.96M | $-1.12M | $-916K | $1.68M |
Revenue by Products
| Product | Q1-2025 | Q3-2025 | Q2-2025 | Q2-2026 |
|---|---|---|---|---|
 Med Device | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ |
 Med Tech | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $40.00M ▲ |
Revenue by Geography
| Region | Q4-2025 | Q3-2025 | Q2-2025 | Q2-2026 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 UNITED STATES | $70.00M ▲ | $60.00M ▼ | $60.00M ▲ | $70.00M ▲ |
CEO
James C. Clemmer
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 84
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:4.6M
Value:$47.1M
DIVISADERO STREET CAPITAL MANAGEMENT, LP
Shares:3.68M
Value:$37.63M
BLACKROCK, INC.
Shares:3.47M
Value:$35.55M
Summary
Showing Top 3 of 194